Immatics N.V. (IMTX) News
Follow Immatics N.V. (IMTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Immatics IMA402 shows 32% confirmed response rate in Phase 1b melanoma trial
Immatics reported a 32% confirmed response rate among high-PRAME melanoma patients in its Phase 1b trial of IMA402.
EQUITY | Oct 26, 2026, 11:35 AM UTC
M
Immatics Reports 32% cORR in Phase 1 PRAME Melanoma Data
Immatics reported 32% cORR in PRAME-high melanoma from Phase 1b IMA402 data and 41% cORR across tumors in Phase 1 IMA203CD8 data. The company described safety as manageable and said next steps include combinations and ta
EQUITY | Oct 24, 2026, 06:34 AM UTC
L
13D Filings — Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holding
EQUITY | Sep 04, 2026, 11:00 PM UTC
H
Moderna, Cadeler, Marvell among stocks rising on Tuesday
Moderna, Cadeler and Marvell Technology trade higher Tuesday alongside other names after analyst upgrades, a higher FY26 sales guide and other company-specific developments.
EARNINGS | Aug 25, 2026, 02:03 PM UTC
M
Immatics (IMTX) announces $150 million underwritten offering
Immatics announces a $150 million underwritten offering, with no further terms, pricing, or proceeds use stated in the provided feed.
EQUITY | Aug 25, 2026, 11:00 AM UTC
L
Immatics (IMTX) announces Q2 2026 financial results and business update
Immatics (IMTX) announces its second quarter 2026 financial results alongside a business update, per TradeXchange Newsdesk.
EARNINGS | Aug 18, 2026, 11:00 AM UTC